Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29947404 | 1.00 | LPL (0.36) | LPLLIPGEGFR | |
| SCHEMBL29739929 | 0.90 | LPL (0.33) | LPLLIPG | |
| SCHEMBL31478095 | 0.84 | LPL (0.38) | LPLLIPGEGFR | |
| SCHEMBL24804122 | 0.83 | SNCA (0.33) | — | |
| SCHEMBL24804126 | 0.83 | CSF1R (0.34) | — | |
| SCHEMBL1494645 | 0.80 | LPL (0.40) | LPLLIPG | |
| SCHEMBL14645675 | 0.79 | LPL (0.39) | LPLLIPG | |
| SCHEMBL29520129 | 0.79 | LPL (0.39) | LPLLIPG | |
| SCHEMBL1494631 | 0.78 | LPL (0.38) | LPLLIPG | |
| SCHEMBL28839065 | 0.76 | F2 (0.31) | LPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | ACCRO BIOSCIENCE HK LTD (HK) | 2026-01-01 | — | — | US | disclosed |
| EP-4337648-B1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12479831-B2 | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-4538268-A1 | PYRIDAZIN-3-CARBOXAMIDE COMPOUND AS TYK2 INHIBITOR | Guangzhou Fermion Technology Co., Ltd. (CN) | 2025-04-16 | — | — | EP | disclosed |
| US-20240317718-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-09-26 | — | — | US | disclosed |
| US-20240124421-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2024-04-18 | — | — | US | disclosed |
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-4337649-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | Bristol-Myers Squibb Company (US) | 2024-03-20 | — | — | EP | disclosed |
| US-11884650-B2 | Substituted heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-01-30 | — | — | US | disclosed |
| WO-2024010963-A1 | HETEROARYL COMPOUNDS AS INHIBITORS OF TYK2/JAK1, COMPOSITION AND APPLICATION THEREOF | ACCRO BIOSCIENCE (HK) LIMITED (CN) | 2024-01-11 | — | — | WO | disclosed |
| EP-4257587-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Shenzhen Chipscreen Biosciences Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2023-06-01 | — | — | US | disclosed |
| WO-2023284869-A1 | SULFUR/PHOSPHORUS-CONTAINING ARYL COMPOUND AND APPLICATION THEREOF | 南京明德新药研发有限公司 | 2023-01-19 | — | — | WO | disclosed |
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-29 | — | — | US | disclosed |
| WO-2022268119-A1 | SULFOXIMINE COMPOUND AND USE THEREOF | 南京明德新药研发有限公司 | 2022-12-29 | — | — | WO | disclosed |
| US-20220388987-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-08 | — | — | US | disclosed |
| US-20220388987-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-08 | — | — | US | disclosed |
| WO-2021222153-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101548-A1 | HYDROXAMATE COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | TYK2, WEE2, WEE1 | LPL 4465/4885LIPG 4086/4885EGFR 1765/4885 |
| US-20230167092-A1 | SUBSTITUTED N-(METHYL-D3)PYRIDAZINE-3-CARBOXAMIDE OR N-(METHYL-D3)-NICOTINAMIDE COMPOUNDS AS IL-12, IL-23 AND/OR IFNALPHA MODULATORS | JAK3, TYK2, IRAK3 | LPL 4864/4885LIPG 4860/4885EGFR 3617/4885 |
| US-11884650-B2 | Substituted heterocyclic compounds | TYK2, JAK2, STAT3 | LPL 4832/4885LIPG 4709/4885EGFR 1022/4885 |
| US-20220411384-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | LPL 4832/4885LIPG 4709/4885EGFR 1022/4885 |
| US-20220388987-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | LPL 4832/4885LIPG 4709/4885EGFR 1022/4885 |
| US-12479831-B2 | Substituted N(-methyl-D3)pyridazine-3-carboxamide or M-(methyl-D3)-nicotinamide compounds as IL-12, IL-23 and/or IFNα modulators | TYK2, IRAK3, JAK3 | LPL 4847/4885LIPG 4855/4885EGFR 2937/4885 |
| US-20260001898-A1 | Heteroaryl compounds as inhibitors of TYK2/JAK1, composition and application thereof | JAK1, JAK2, TYK2 | LPL 4018/4885LIPG 3472/4885EGFR 423/4885 |
| US-20240317718-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, JAK1 | LPL 4800/4885LIPG 4670/4885EGFR 957/4885 |
| US-20240124421-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS | TYK2, JAK2, STAT3 | LPL 4832/4885LIPG 4709/4885EGFR 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.